APLIF (Appili Therapeutics) Moat Score: 2/10 (As of Jun. 27, 2026)


What is Appili Therapeutics Moat Score?

Appili Therapeutics APLIF Moat Score is 2 as of Jun. 27, 2026. The stock has 4 warning signs investors should review. Among 1,404 Biotechnology companies, Appili Therapeutics ranks better than 58.12% on this metric.

Appili Therapeutics has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Appili Therapeutics has No Moat: Appili Therapeutics Inc has very weak competitive advantages. It operates in the pharmaceutical industry with limited market share, lacks significant patents or proprietary technology, and faces high competition and regulatory challenges.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Appili Therapeutics might have No Moat - Very weak/transient advantages.

Appili Therapeutics  (OTCPK:APLIF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Appili Therapeutics Moat Score Related Terms

APLIF vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Appili Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Appili Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Appili Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Appili Therapeutics's Moat Score falls into.


Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Appili Therapeutics (APLIF) has a Moat Score of 2 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Appili Therapeutics ranks #588 out of 1404 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Appili Therapeutics' Moat Score too high?
Appili Therapeutics' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Appili Therapeutics' value of 2 is 0% at this industry median. Based on the distribution chart, Appili Therapeutics ranks #588 out of 1404 companies in the Biotechnology industry, which is above the industry midpoint.
How does Appili Therapeutics' Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Appili Therapeutics ranks #588 out of 1404 companies for Moat Score. This puts Appili Therapeutics in the upper half of its industry. The industry median Moat Score is 2.00. Appili Therapeutics' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Appili Therapeutics's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Appili Therapeutics's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Appili Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Appili Therapeutics (APLIF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 13% above its estimated fair value. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Appili Therapeutics (APLIF), the current Moat Score is 2 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Appili Therapeutics Business Description

Other Exchanges APLI:Canada
Address 1344 Summer Street, Suite 21, Halifax, NS, CAN, B3H 0A8
Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes programs namely ATI-1701, ATI-1801.